{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:33:45Z","timestamp":1768638825857,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5111-1","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T08:28:24Z","timestamp":1543912104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Expression of the immune checkpoint receptor TIGIT in Hodgkin\u2019s lymphoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Wenchao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niclas C.","family":"Blessin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-4258","authenticated-orcid":false,"given":"Ronald","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Hube-Magg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Makrypidi-Fraune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Wellge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Mandelkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus F.","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"H\u00f6flmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Lennartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob R.","family":"Izbicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Minner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"B\u00fcscheck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ria","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Krech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas M.","family":"Luebke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Wittmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eike","family":"Burandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Wilczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hinsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"issue":"1","key":"5111_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrc2542","volume":"9","author":"R Kuppers","year":"2009","unstructured":"Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5111_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2559.2010.03696.x","volume":"58","author":"E Roman","year":"2011","unstructured":"Roman E, Smith AG. Epidemiology of lymphomas. Histopathology. 2011;58(1):4\u201314.","journal-title":"Histopathology"},{"issue":"4","key":"5111_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1346-8138.2004.tb00680.x","volume":"31","author":"S Erkilic","year":"2004","unstructured":"Erkilic S, Erbagci Z, Kocer NE, Bayazit YA, Camci C. Cutaneous involvement in Hodgkin's lymphoma: report of two cases. J Dermatol. 2004;31(4):330\u20134.","journal-title":"J Dermatol"},{"issue":"1","key":"5111_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","volume":"5","author":"V Diehl","year":"2004","unstructured":"Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma--diagnosis and treatment. Lancet Oncol. 2004;5(1):19\u201326.","journal-title":"Lancet Oncol"},{"issue":"4","key":"5111_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"5111_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"5111_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31\u201341.","journal-title":"Lancet Oncol"},{"issue":"2","key":"5111_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/08820139.2016.1237524","volume":"46","author":"XG Liu","year":"2017","unstructured":"Liu XG, Hou M, Liu Y. TIGIT, a novel therapeutic target for tumor immunotherapy. Immunol Investig. 2017;46(2):172\u201382.","journal-title":"Immunol Investig"},{"issue":"1","key":"5111_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"NA Manieri","year":"2017","unstructured":"Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the Cancer immunity cycle. Trends Immunol. 2017;38(1):20\u20138.","journal-title":"Trends Immunol"},{"key":"5111_CR10","doi-asserted-by":"crossref","unstructured":"Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, et al. Patterns of TIGIT expression in normal lymphatic tissue, inflammation and cancer. Disease Markers. 2018. In Press.","DOI":"10.1158\/1538-7445.AM2018-696"},{"issue":"6","key":"5111_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923\u201337.","journal-title":"Cancer Cell"},{"issue":"5","key":"5111_CR12","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"JM Chauvin","year":"2015","unstructured":"Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015;125(5):2046\u201358.","journal-title":"J Clin Invest"},{"issue":"12","key":"5111_CR13","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H. T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res. 2016;22(12):3057\u201366.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5111_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ccell.2014.11.016","volume":"26","author":"KE Pauken","year":"2014","unstructured":"Pauken KE, Wherry EJ. TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit. Cancer Cell. 2014;26(6):785\u20137.","journal-title":"Cancer Cell"},{"issue":"3","key":"5111_CR15","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","volume":"186","author":"N Joller","year":"2011","unstructured":"Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, Sharpe AH, Kuchroo VK. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186(3):1338\u201342.","journal-title":"J Immunol"},{"issue":"21","key":"5111_CR16","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-16-0933","volume":"22","author":"SJ Blake","year":"2016","unstructured":"Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. Molecular pathways: targeting CD96 and TIGIT for Cancer immunotherapy. Clin Cancer Res. 2016;22(21):5183\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5111_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/imr.12518","volume":"276","author":"WC Dougall","year":"2017","unstructured":"Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276(1):112\u201320.","journal-title":"Immunol Rev"},{"issue":"11","key":"5111_CR18","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1172\/JCI81187","volume":"125","author":"S Kurtulus","year":"2015","unstructured":"Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK, Anderson AC. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125(11):4053\u201362.","journal-title":"J Clin Invest"},{"issue":"6","key":"5111_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nbt0617-487","volume":"35","author":"K Garber","year":"2017","unstructured":"Garber K. Industry \u2018road tests\u2019 new wave of immune checkpoints. Nat Biotechnol. 2017;35(6):487\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"5111_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48\u201357.","journal-title":"Nat Immunol"},{"issue":"5","key":"5111_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"6","key":"5111_CR22","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1007\/s13277-015-4622-5","volume":"37","author":"YW Koh","year":"2016","unstructured":"Koh YW, Jeon YK, Yoon DH, Suh C, Huh J. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumour Biol. 2016;37(6):7507\u201314.","journal-title":"Tumour Biol"},{"issue":"16","key":"5111_CR23","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","volume":"122","author":"P Greaves","year":"2013","unstructured":"Greaves P, Clear A, Owen A, Iqbal S, Lee A, Matthews J, Wilson A, Calaminici M, Gribben JG. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood. 2013;122(16):2856\u201363.","journal-title":"Blood"},{"issue":"12","key":"5111_CR24","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","volume":"113","author":"B Chetaille","year":"2009","unstructured":"Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F, Casasnovas O, Petrella T, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009;113(12):2765\u20133775.","journal-title":"Blood"},{"issue":"12","key":"5111_CR25","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.humpath.2010.05.010","volume":"41","author":"HR Churchill","year":"2010","unstructured":"Churchill HR, Roncador G, Warnke RA, Natkunam Y. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. Hum Pathol. 2010;41(12):1726\u201334.","journal-title":"Hum Pathol"},{"issue":"12","key":"5111_CR26","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","volume":"40","author":"S Muenst","year":"2009","unstructured":"Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol. 2009;40(12):1715\u201322.","journal-title":"Hum Pathol"},{"issue":"6","key":"5111_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/PAI.0000000000000200","volume":"24","author":"TT Nguyen","year":"2016","unstructured":"Nguyen TT, Frater JL, Klein J, Chen L, Bartlett NL, Foyil KV, Kreisel FH. Expression of TIA1 and PAX5 in classical Hodgkin lymphoma at initial diagnosis may predict clinical outcome. Appl Immunohistochem Mol Morphol. 2016;24(6):383\u201391.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"7","key":"5111_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2015.132761","volume":"101","author":"S Vardhana","year":"2016","unstructured":"Vardhana S, Younes A. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica. 2016;101(7):794\u2013802.","journal-title":"Haematologica"},{"issue":"3","key":"5111_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170\u201381.","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"5111_CR30","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268\u201377.","journal-title":"Blood"},{"issue":"8\u20139","key":"5111_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10719-012-9379-0","volume":"29","author":"F Cedeno-Laurent","year":"2012","unstructured":"Cedeno-Laurent F, Dimitroff CJ. Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj J. 2012;29(8\u20139):619\u201325.","journal-title":"Glycoconj J"},{"issue":"3","key":"5111_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF02889938","volume":"31","author":"S Poppema","year":"1979","unstructured":"Poppema S, Kaiserling E, Lennert K. Nodular paragranuloma and progressively transformed germinal centers. Ultrastructural and immunohistologic findings. Virchows Arch B Cell Pathol Incl Mol Pathol. 1979;31(3):211\u201325.","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"5111_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40164-015-0022-1","volume":"4","author":"A Sattarzadeh","year":"2015","unstructured":"Sattarzadeh A, Diepstra A, Rutgers B, van den Berg A, Visser L. CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma. Exp Hematol Oncol. 2015;4:27.","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"5111_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s13075-014-0469-1","volume":"16","author":"S Ceeraz","year":"2014","unstructured":"Ceeraz S, Nowak EC, Burns CM, Noelle RJ. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther. 2014;16(5):469.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"5111_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11882-017-0740-z","volume":"17","author":"AS Tocheva","year":"2017","unstructured":"Tocheva AS, Mor A. Checkpoint inhibitors: applications for autoimmunity. Curr Allergy Asthma Rep. 2017;17(10):72.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"8","key":"5111_CR36","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/PAS.0b013e318165b0d6","volume":"32","author":"SH Nam-Cha","year":"2008","unstructured":"Nam-Cha SH, Roncador G, Sanchez-Verde L, Montes-Moreno S, Acevedo A, Dominguez-Franjo P, Piris MA. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol. 2008;32(8):1252\u20137.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"5111_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/path.2711","volume":"221","author":"D Aldinucci","year":"2010","unstructured":"Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin\u2019s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221(3):248\u201363.","journal-title":"J Pathol"},{"issue":"9","key":"5111_CR38","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394.","journal-title":"Lancet Oncol"},{"issue":"11","key":"5111_CR39","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183\u201394.","journal-title":"Blood"},{"issue":"4","key":"5111_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203\u201320.","journal-title":"Nat Rev Clin Oncol"},{"issue":"31","key":"5111_CR41","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, et al. Programmed Death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure. J Clin Oncol. 2016;34(31):3733\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"5111_CR42","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(9):4275\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"34","key":"5111_CR43","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, et al. Safety and efficacy of Nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35(34):3851\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"5111_CR44","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/modpathol.3800208","volume":"17","author":"M Mirlacher","year":"2004","unstructured":"Mirlacher M, Kasper M, Storz M, Knecht Y, Durmuller U, Simon R, Mihatsch MJ, Sauter G. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol. 2004;17(11):1414\u201320.","journal-title":"Mod Pathol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5111-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T19:14:50Z","timestamp":1575400490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5111-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5111"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5111-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this study was obtained from the local ethics board (WF-049\/09, Ethics Commission of the \u00c4rztekammer Hamburg).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1209"}}